Risperdal, manufactured by Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), was heavily marketed off-label to physicians treating elderly patients from 1999 to 2005, despite the drug not being FDA-approved for treating dementia, Alzheimer’s disease, depression, or anxiety in seniors. This aggressive marketing campaign resulted in multiple major settlements, including a $2.2 billion settlement with the federal government in 2013 and a $181 million settlement with 36 state attorneys general in 2012. The off-label promotion led to widespread prescription of Risperdal to vulnerable elderly populations, resulting in serious health risks and a class action lawsuit that highlights how pharmaceutical companies can prioritize profit over patient safety.
The core issue centers on a deliberate strategy: Janssen created a dedicated “ElderCare” marketing team to promote Risperdal’s unapproved uses specifically to doctors treating seniors. Physicians were offered financial incentives, consulting contracts, and speaker fees to learn about and prescribe the drug for conditions it was never tested for in elderly patients. When the FDA eventually issued a black box warning in 2005 stating that elderly dementia patients taking antipsychotics like Risperdal faced increased risk of death, it became clear that the marketing campaign had known of these dangers while actively pushing the drug to vulnerable populations.
Table of Contents
- How Janssen Promoted Risperdal Off-Label to Elderly Physicians
- Off-Label Uses Targeted to Elderly Populations Without FDA Approval
- The $2.2 Billion Federal Settlement and Criminal Charges
- The $181 Million State Attorneys General Settlement
- FDA Safety Warnings and What They Revealed
- Who Was Harmed and Why Elderly Patients Were Vulnerable
- Legal Lessons and Changes in Pharmaceutical Marketing Oversight
- Conclusion
How Janssen Promoted Risperdal Off-Label to Elderly Physicians
Between 1999 and 2005, Janssen established an unprecedented marketing infrastructure specifically designed to push risperdal to doctors treating elderly patients. The ElderCare marketing team operated with clear messaging: position Risperdal as a treatment for behavioral symptoms in dementia and Alzheimer’s patients, even though the drug was only FDA-approved for schizophrenia. Sales representatives were trained to emphasize benefits while downplaying or omitting information about serious risks. For example, a typical physician conversation would focus on how Risperdal could calm agitated dementia patients, without adequately explaining that the drug had never been tested in this population and could increase mortality risk. The financial incentive structure was crucial to Risperdal’s off-label expansion. Janssen didn’t simply rely on direct-to-physician sales pitches.
Instead, the company offered lucrative consulting contracts, speaker fees, and educational grants to influential physicians and opinion leaders. These payments created a system where doctors who prescribed more Risperdal to elderly patients could earn substantial side income. Unlike transparent marketing that discloses drug limitations, this model effectively turned prescribers into salespeople while creating undisclosed financial conflicts of interest. A physician might receive $5,000 to speak at a local hospital about Risperdal’s “benefits,” but that same presentation would omit the FDA’s safety concerns. The scope of this marketing effort was substantial. Janssen distributed promotional materials to physicians’ offices, sponsored medical education events, and funded continuing medical education (CME) courses where speakers—often paid by Janssen—presented Risperdal as an appropriate choice for elderly dementia patients. This multi-channel approach ensured that the off-label message reached the broadest possible audience of prescribers, multiplying the number of elderly patients who received the drug for unapproved uses.
Off-Label Uses Targeted to Elderly Populations Without FDA Approval
Janssen marketed Risperdal for four primary off-label uses in elderly patients: dementia-related behavioral symptoms, Alzheimer’s disease, depression, and anxiety. None of these indications had been approved by the FDA. The critical distinction is that FDA approval is based on clinical trials demonstrating safety and efficacy in specific populations. Risperdal’s approval was limited to schizophrenia treatment in adults. Elderly patients metabolize medications differently than younger adults, experience more drug interactions due to multiple medications, and are generally more vulnerable to serious side effects. Marketing an untested antipsychotic to this vulnerable population represented a significant departure from ethical pharmaceutical practice.
The marketing materials themselves often contained misleading or incomplete information. Sales representatives would emphasize behavioral control in dementia patients while minimizing mentions of stroke risk, weight gain, metabolic problems, and increased mortality. In one documented example, Janssen marketing materials suggested Risperdal was beneficial for “behavioral problems” in nursing home residents without clearly stating these claims lacked FDA support. Physicians who prescribed Risperdal based on this marketing were making treatment decisions without complete safety information, ultimately exposing their elderly patients to undisclosed risks. Importantly, the FDA had begun identifying safety concerns as early as 2003, issuing a warning about Risperdal’s effects on elderly patients. Yet Janssen’s marketing continued largely unabated, suggesting the company prioritized revenue from off-label use over compliance with emerging safety data. This represents a significant ethical breach: a pharmaceutical manufacturer continued promoting a drug to a high-risk population even after federal regulators flagged safety concerns.
The $2.2 Billion Federal Settlement and Criminal Charges
In November 2013, Johnson & Johnson and Janssen Pharmaceuticals agreed to pay $2.2 billion to resolve charges brought by the U.S. Department of Justice. This settlement was not merely a civil matter—Janssen pled guilty to a criminal misdemeanor charge of misbranding Risperdal as a treatment for elderly dementia patients. Criminal guilty pleas from pharmaceutical manufacturers are relatively rare and underscore the severity of the conduct. The $2.2 billion figure represented the largest settlement to that point for off-label marketing and signaled that federal prosecutors viewed the violations as intentional and systematic. The settlement included not just the $2.2 billion payment but also criminal sanctions and compliance obligations.
The criminal guilty plea meant that a federal court determined there was sufficient evidence that Janssen knowingly and willfully misbranded Risperdal. This distinction matters because it separates cases where a company made innocent mistakes from cases where misconduct was deliberate. The Department of Justice’s prosecution specifically focused on the period during which Janssen marketed Risperdal for off-label uses in elderly populations, directly connecting the company’s marketing strategy to the criminal violation. In addition to the federal settlement, Janssen faced significant reputational and financial consequences. The criminal conviction meant the company became subject to enhanced monitoring programs and faced restrictions on government contracts. For a manufacturer that derives substantial revenue from Medicare and Medicaid prescriptions (the federal health insurance programs for elderly and disabled Americans), these restrictions had tangible business impact beyond the settlement amount itself.
The $181 Million State Attorneys General Settlement
Beyond federal charges, the off-label marketing prompted action by state attorneys general. In August 2012, Oregon Attorney General Ellen F. Rosenblum and 36 other state attorneys general reached a $181 million settlement with Janssen over unfair and deceptive marketing practices related to Risperdal in elderly populations. This multi-state action was significant because it represented coordination among state regulators who identified a common pattern of deceptive conduct affecting their respective populations. The settlement focused specifically on marketing practices rather than product defect, meaning the states had identified how Janssen promoted the drug as the core problem. The state settlement addressed marketing claims that Janssen knew or should have known were false or misleading.
Specifically, the state attorneys general challenged Janssen’s promotional materials suggesting Risperdal was safe and effective for elderly patients with dementia, behavioral problems, and other off-label uses. Unlike a private lawsuit where individual victims must prove they were harmed, the state settlements operate on a broader consumer protection theory: the company engaged in unfair business practices that deceived the buying public (in this case, physicians and patients). This allowed states to take action without waiting for individual lawsuits to accumulate. The $181 million figure, while substantial, was roughly one-tenth of the federal settlement amount. This reflects different calculation methodologies and the fact that the federal settlement included additional penalties and compliance costs. However, the multi-state nature of the settlement demonstrated that Risperdal’s off-label marketing had affected elderly populations across the entire country, not merely in a single jurisdiction. Every state that participated had identified the same deceptive marketing conduct in their own healthcare system.
FDA Safety Warnings and What They Revealed
The FDA issued an initial warning about Risperdal’s effects on elderly dementia patients in 2003. This warning reflected emerging safety data suggesting that antipsychotic medications, including Risperdal, carried risks when used in elderly patients for behavioral symptoms. However, the 2003 warning was less stringent than subsequent actions—it alerted prescribers without blocking the medication’s sale or dramatically restricting prescribing. For a company like Janssen, a warning without a black box restriction could be interpreted as a manageable regulatory speed bump rather than a clear prohibition. By 2005, the FDA’s concern had escalated substantially. The agency added a black box warning to Risperdal’s label—the most serious warning the FDA can impose short of removing a drug from the market.
The black box warning stated explicitly that elderly patients with dementia-related psychosis treated with antipsychotics like Risperdal face an increased risk of death. This warning was based on clinical trial data and adverse event reporting that showed a measurable mortality signal: elderly dementia patients taking Risperdal were more likely to die than those receiving other treatments. For a pharmaceutical company, a black box warning is a serious regulatory event that typically prompts significant changes to marketing and prescribing practices. What makes Janssen’s continued off-label promotion particularly troubling is the timeline: the company had marketed Risperdal aggressively for off-label elderly use throughout the period when FDA safety concerns were emerging. The 2005 black box warning represented an official, unambiguous statement that the drug posed serious risks to the very population Janssen had been targeting. Yet the settlements and subsequent investigations revealed that Janssen’s marketing evolution did not fully align with the FDA’s escalating safety warnings. This pattern—continuing aggressive marketing despite emerging safety data—formed the core of the Department of Justice’s criminal case.
Who Was Harmed and Why Elderly Patients Were Vulnerable
Elderly patients with dementia, Alzheimer’s disease, and related conditions are among the most vulnerable populations in healthcare. Many lack decision-making capacity and rely on family members, healthcare providers, or facility staff to make medical decisions on their behalf. When a physician recommends Risperdal, an elderly dementia patient may lack the cognitive ability to understand the drug’s risks or question the physician’s judgment. This vulnerability was precisely what made off-label Risperdal marketing particularly problematic: the target population could not meaningfully resist or question the medication that healthcare providers prescribed. The harm was not merely theoretical. Elderly patients who received Risperdal for off-label uses like dementia-related agitation experienced serious side effects including stroke, metabolic complications, weight gain, and in some cases death.
Because these patients often couldn’t articulate their symptoms or side effects, and because prescribers were motivated by the marketing (and sometimes by financial incentives from Janssen), problematic prescribing patterns went undetected for years. A family might notice their elderly relative becoming more sedated or experiencing a fall, but the connection between Risperdal and these outcomes might not be immediately apparent, especially if the medication had been portrayed to the family as beneficial for behavioral management. Nursing homes and long-term care facilities were particularly affected. These institutions care for elderly patients, many with dementia, and face pressure to manage behavioral symptoms efficiently. Risperdal, marketed as effective for behavioral control, became widely used in these settings. The combination of vulnerable residents, institutional pressure to manage behavior, and aggressive pharmaceutical marketing created an environment where off-label use flourished with minimal oversight.
Legal Lessons and Changes in Pharmaceutical Marketing Oversight
The Risperdal off-label marketing case became a landmark example of how pharmaceutical companies can systematically violate rules designed to protect public health. The case prompted increased scrutiny of pharmaceutical marketing practices, leading to enhanced oversight by the FDA and the Department of Justice. The very fact that Janssen pled guilty to criminal charges signaled that pharmaceutical off-label promotion could cross the line from aggressive marketing into criminal conduct. This legal outcome fundamentally changed how pharmaceutical companies approach marketing in subsequent years.
The settlements also prompted policy discussions about controlling off-label promotion while still allowing physicians appropriate freedom to prescribe based on clinical judgment. The FDA and medical community generally accept that physicians may prescribe drugs for off-label uses, which is legal and sometimes appropriate when supported by evidence. The violation in Janssen’s case was not merely that Risperdal was prescribed off-label—it was that the manufacturer actively promoted off-label uses through marketing, financial incentives to physicians, and misleading information. This distinction between permitted off-label prescribing (by individual physicians) and prohibited off-label promotion (by manufacturers) has become clearer in post-settlement regulatory practice. Pharmaceutical companies now face stricter compliance requirements around marketing claims, physician payments, and advertising of unapproved uses.
Conclusion
The Risperdal off-label marketing case demonstrates how pharmaceutical companies can exploit regulatory gray areas to expand drug use beyond FDA-approved indications, particularly targeting vulnerable populations like elderly patients with dementia. The $2.2 billion federal settlement, criminal guilty plea, and $181 million state settlement represent unprecedented enforcement actions that held Janssen accountable for a systematic marketing strategy that prioritized profit over patient safety. The 2005 FDA black box warning—stating that elderly dementia patients faced increased death risk—came only after years of aggressive off-label promotion, showing how safety concerns and aggressive marketing can advance on separate timelines.
If you received Risperdal off-label for dementia, Alzheimer’s disease, depression, or anxiety as an elderly patient and experienced serious health consequences including stroke, cardiovascular events, metabolic complications, or loss of a family member, you may have rights to compensation through the existing settlements or other legal remedies. Consulting with an attorney experienced in pharmaceutical injury cases can help evaluate your specific situation, determine applicable settlement claims, and explore whether additional compensation may be available. The Risperdal case serves as a reminder that pharmaceutical marketing practices matter—they directly influence prescribing decisions and ultimately affect patient health and safety.